Posted by Michael Wonder on 19 Mar 2021
Ovarian cancer patients to have NICE approved drug combination option on Cancer Drugs Fund
19 March 2021 - A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund, following its approval by NICE in draft guidance published today.
The draft guidance recommends olaparib (Lynparza, AstraZeneca) used with bevacizumab (Avastin, Roche) as an option for people whose cancer has had a complete or partial response after first-line treatment with platinum-based chemotherapy and bevacizumab.
The cancer must also test positive for homologous recombination deficiency.
